Drug Trial Radar · NCT01733966
A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults
Last checked: Nov 20, 2026Latest source record: Sep 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
100
Actual
Start
May 2010
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Quanta MedicalIndustry
- Sponsor type
- Industry
- Collaborators
- Laboratoires Iprad-Vegebom
- First posted
- Nov 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary outcome measure is to compare efficacy of an association of Secnidazol(2g)-Ciprofloxacin(1g) (during 3 days) versus 3g of Amoxicillin-Clavulanic Acid during 10 days for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults in clinical and biological cure. The cure rate will be evaluated at the second visit (14 days after the inclusion visit)
Conditions
- Diverticular Sigmoïditis
Interventions
Secnidazole, ciprofloxacineDrug
2g of microgranules of secnidazole. a single dose per day during 3 days. 1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)
Amoxicillin-Clavulanic AcidDrug
3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- comparaison of the efficacy of an association of Secnidazol(2g)-Ciprofloxacin(1g) (during 3 days) versus 3g of Amoxicillin-Clavulanic Acid during 10 days for clinical and biological cureTime frame: the cure rate will be evaluated at the second visit (14 days after the inclusion visit)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.